|801-2, Jindong Mansion, No. 536 Xueshi Road, Yinzhou, Ningbo 315100, P.R.Chinafirstname.lastname@example.org|
|Place of Origin:||China|
|Model Number:||Film coated Tablets, 0.3mg, 0.45mg, 0.625mg,0.9mg, 1.25mg|
|Minimum Order Quantity:||20000 boxes|
|Packaging Details:||28’s/blister, box|
|Payment Terms:||L/C, T/T|
|Supply Ability:||one million pills per day|
|Product:||Conjugated Estrogens Film Coated Tablets||Specification:||Film Coated Tablets, 0.3mg, 0.45mg, 0.625mg,0.9mg, 1.25mg|
|Standard:||In - House||Packing:||28’s/blister, Box|
Film Coated Oral Medications Premarin Conjugated Estrogens Tablets
Product : Conjugated Estrogens Film Coated Tablets
Specification : Film coated Tablets, 0.3mg, 0.45mg, 0.625mg,0.9mg, 1.25mg
Standard : In - house
Packing : 28’s/blister, box
Conjugated estrogens tablets, USP, for oral administration contains a mixture of conjugated estrogens obtained exclusively from natural sources, occurring as the sodium salts of water-soluble estrogen sulfates blended to represent the average composition of material derived from pregnant mares' urine. It is a mixture of sodium estrone sulfate and sodium equilin sulfate. It contains as concomitant components, as sodium sulfate conjugates, 17α-dihydroequilin, 17α-estradiol, and 17β-dihydroequilin. Tablets for oral administration are available in 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg strengths of conjugated estrogens.
Indications and Usage :
Conjugated Estrogens Film coated tablets therapy is indicated in the:
1. Treatment of moderate to severe vasomotor symptoms due to menopause.
2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.
3. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure.
4. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease.
5. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).
6. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate.
The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.
Contact Person: Luke Liu